Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Nov
01
Today In Oncology
OptiTROP-Lung06 A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?
How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation
Selpercatinib Sacituzumab Govitecan Show Activity in Thyroid Cancer Subtypes
ASTRO Updates Guideline on Shorter-Course Radiation Therapy for Localized Prostate Cancer
High-Risk Melanoma Personalized mRNA Vaccine Plus Immunotherapy Reduces Risk of Recurrence After Surgery
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo